In the rat, the ability of drugs to lower brain stimulation reward (BSR) thresholds often correlates with high abuse liability.
Introduction 3,4-Methylenedioxypyrovalerone (MDPV), a synthetic cathinone with important reported toxicity and high abuse potential, has been increasingly used since the last 5 years.
Whilst higher abuse concentrations triggered the need for attention to prevention in these locations, it is the features of the abuse in each context that informs the prevention approach to be undertaken.
Synthetic cathinone's potent stimulatory effects, coupled with their high abuse potential, and propensity for addiction demands additional pharmacological and toxicological evaluations for these existing and new designer drugs of abuse.
In 2011, the United States Drug Enforcement Agency DEAA) temporarily classified mephedrone, 3,4-methylenedioxypyrovalerone (MDPV), and methylone as Schedule 1 drugs, a designation that indicates drugs with no accepted medical use and very high abuse liability [13].
More importantly, the composite regained the most of its reversible capacity (742 mAh g−1) when the discharge rate was modulated back to 0.5 C, which shows a high abuse tolerance of the S/N-CNT composite.
These results not only illustrate that the CNT of the NMO/CNT composite has enhanced reversible capacity, but also indicate that the NMO material has the high abuse tolerance that can exhibit excellent rate performance.
